MedElevator Войти в исследования
← Поиск публикаций

DOI 10.19746/j.cnki.issn.1009-2137.2021.06.009

Медицинская библиотека · Zhongguo shi yan xue ye xue za zhi · 2021

[A Retrospective Analysis of TKI Discontinuation in Patients with CML].

Zhao Xiao-Li, Hong Ming, Qiao Chun, Sun Qian, Zhu Han, Wang Shuai, Li Jian-Yong, Qian Si-Xuan, Zhu Yu

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To investigate the clinical characteristics of the patients with chronic myeloid leukemia (CML) discontinued tyrosine kinase inhibitors (TKI) therapy and the outcome of the patients.

METHODS

35 cases of CML patients experienced initiative discontinuation of TKI therapy in our hospital from June 1st 2015 to December 31th 2019 were retrospectively analyzed. The TFR of the patients and the factors affecting it were analyzed.

RESULTS

The median duration of TKI administration was 72 (range 35-173) months in the 35 patients. Among these patients, 8 had experienced TKI dose reduction or suspension. All the enrolled patients have achieved at least MMR. The median time for these patients achieving MMR was 15 (range 3-75) months after administration of TKI, and for MMR maintenance before TKI suspension was 55 (range 13-164) months. After TKI withdrawal the median follow up time was 20.3 (range 3-57.9) months, 22 out of 35 patients kept TFR, among them, 2 (5.71%) patients restarted TKI after 12 month suspension, and maintained MMR during suspension. 13 (37.1%)patients lost MMR, among them, 9 patients restarted TKI treatment, and 5 of them achieved MR4.0 after the median duration of 3(2-5) month. No patients were found to have disease progression. The estimated TFR rate was 57.8% and 51.8% at 12 and 24 months after discontinuation, respectively. Other clinical characteristic related to relapse were also analyzed, including the cumulative TKI administration duration, cumulative MMR duration, time to achieve MMR, median age at diagnosis, risk stratification by Sokal score, TKI dose reduction and discontinuation history, and second-generation TKI administration before stopping TKI, however, no statistical difference was found.

CONCLUSION

TKI discontinuation is practical for CML patients in our center.

Для цитирования: Zhao Xiao-Li, Hong Ming, Qiao Chun, Sun Qian, Zhu Han, Wang Shuai, Li Jian-Yong, Qian Si-Xuan, Zhu Yu. [A Retrospective Analysis of TKI Discontinuation in Patients with CML].. Zhongguo shi yan xue ye xue za zhi. 2021. DOI: 10.19746/j.cnki.issn.1009-2137.2021.06.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.